



October 23, 2017

**The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi.**

GlaxoSmithKline Consumer
Healthcare Pakistan Limited
35-Dockyard Road,
West Wharf,
Karachi - 74000,
Pakistan

UAN +92 21 111 475 725
Fax +92 21 3220 1855
www.gsk.com.pk

SUBJECT: DISCLOSURE OF MATERIAL INFORMATION

Dear Sirs,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following:

At a meeting of the Board of Directors of GlaxoSmithKline Consumer Healthcare Pakistan Limited (“**Company**”) held at 12:30 hours on October 23, 2017 at the registered office of the Company, the Board of Directors passed the following resolution:


Subject to (a) approval of the shareholders of the Company in an Extra Ordinary General Meeting and (b) compliance of all requirements of the Companies Act of 2017, the Board of Directors of the Company approved the extension of the term of the loan made to the Company GSK OTC (Private) Limited by way of a finance facility for a further period of 11 (eleven) months for the amount of equivalent PKR of up to USD 10,000,000 to enhance the capital and thereby enabling and strengthen its economic, technical and operational ability. The interest rate on each instalment of funds shall be equal to the rate quoted by Citi Bank Pakistan for advances/loans in Pakistani Rupees for respective interest period, quoted at least two working days before/on the date on which the interest period commences.

*The Board of Directors also approved increasing of the Authorized Share Capital of the Company to PKR 2,000,000,000 (Pak Rupees Two Billion Only) from PKR 1,000,000,000 (Pak Rupees One Billion Only) under Section 85 of the Companies Act, 2017 (“**Act**”) in order to enable it to subsequently issue further shares under Section 83 of the Act, whenever required. For the above-mentioned purpose the Board of Directors approved the alteration of the Capital Clause in the Memorandum of Association of the Company by passing a special resolution.*

Further, the Board shall also consider possible business combination options with GlaxoSmithKline OTC Private Limited.

A disclosure form as required under S.R.O. 143(1)/2012 dated December 5, 2012 read with Section 131 of the Securities Act, 2015 is also enclosed as Annexure A.

Yours Faithfully,


**Farhan M. Haroon
Company Secretary**

K.A
Copy: Commissioner, Company Law Division
Securities and Exchange Commission of Pakistan
NIC Building, Jinnah Avenue,
Blue Area, Islamabad.



ANNEXURE A
DISCLOSURE FORM
IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company:	GlaxoSmithKline Consumer Healthcare Pakistan Limited 35 Dockyard Road, West Wharf, Karachi, 74000 - Pakistan
Date of Report:	23 October, 2017
Contact Information:	Farhan M. Haroon Company Secretary 35 Dockyard Road, West Wharf, Karachi 74000 – Pakistan. Telephone: +92 (21) 3520 2083 Fax Number: +92 21 3220 1386 Email Address: farhan.m.haroon@gsk.com

[√] Disclosure of inside information by listed company in terms of Section 15 D (1).

Public disclosure of inside information, which directly concerns the listed securities

At a meeting of the Board of Directors of GlaxoSmithKline Consumer Healthcare Pakistan Limited (“**Company**”) held at 12:30 hours on October 23, 2017 at the registered office of the Company, the Board of Directors passed the following resolution:

Subject to (a) approval of the shareholders of the Company in an Extra Ordinary General Meeting and (b) compliance of all requirements of the Companies Act of 2017, the Board of Directors of the Company approved the loan by way of a finance facility to made to the Company GSK OTC (Private) Limited for a period of 11 (eleven) months for the amount of equivalent PKR of up to USD 10,000,000 to enhance the capital and thereby enabling and strengthen its economic, technical and operational ability. The interest rate on each instalment of funds shall be equal to the rate quoted by Citi Bank Pakistan for advances/loans in Pakistani Rupees for respective interest period, quoted at least two working days before/on the date on which the interest period commences.

*The Board of Directors also approved increasing of the Authorized Share Capital of the Company to PKR 2,000,000,000 (Pak Rupees Two Billion Only) from PKR 1,000,000,000 (Pak Rupees One Billion Only) under Section 85 of the Companies Act, 2017 (“**Act**”) in order to enable it to subsequently issue further shares under Section 83 of the Act, whenever required. For the above-mentioned purpose the Board of Directors approved the alteration of the Capital Clause in the Memorandum of Association of the Company by passing a special resolution.*

Further, the Board shall also consider possible business combination options with GlaxoSmithKline OTC Private Limited. The Company has duly caused this form / statement to be signed / on its behalf by the undersigned hereunto duly authorized.

Farhan M. Haroon
Company Secretary
Dated: October 23, 2017